Is Evoke Pharma, Inc. (EVOK) a Buy, Sell, or Hold?
Evoke Pharma, Inc.
NASDAQ:EVOK
$11 USD
$11 (0%)
- Volume
- 47.1K
- Average Volume
- 100.37K
- Market Capitalization
- $18.95M
- P/E Ratio
- -6.96
- Dividend Yield
- 0.00%
- Price Target
- $18.00
- Year High
- $11.00
- Year Low
- $1.94
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.27
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Mark A. Kowieski |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Current Symbol | EVOK |
| CUSIP | 30049G302 |
| CIK | 0001403708 |
| Web | https://www.evokepharma.com |
| Phone | 858 345 1494 |
| Currency | USD |
| Employees | 3 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.52 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.27 |
| Quick Ratio | 1.22 |
| Cash Ratio | 0.95 |
Sales & Book Value
| Annual Sales | $10.25M |
| Price / Sales | 1.70 |
| Cash Flow | -0.82 |
| Price / Cash Flow | -9.09 |
| Price / Book | 8.37 |
Price Target and Rating
| Average Stock Price Forecast | $18.00 |
| High Stock Price Forecast | $18.00 |
| Low Stock Price Forecast | $18.00 |
| Forecast Upside/Downside | -38.89% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 12 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.81 |
| Trailing P/E Ratio | -6.96 |
| PEG Ratio | -0.04 |
| P/E Growth | -0.04 |
| Net Income | $-5.35M |
| Net Margin | -36.28% |
| Pretax Margin | -36.28% |
| Return on Equity | -89.12% |
| Return on Assets | -25.77% |
Financials Score
| AltmanZ Score | -10.78 |
| Piotroski Score | 3.00 |
| Working Capital | 3.3M |
| Total Assets | 15.65M |
| Ebit | -4.73M |
| Market Cap | 18.95M |
| Total Liabilities | 12.29M |
Poll Results
About Evoke Pharma, Inc. (NASDAQ:EVOK) Stock
Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials. This medicine is being developed to mitigate symptoms associated with both acute and recurring diabetic gastroparesis, specifically in female patients. Evoke Pharma distributes its offerings to a broad base of healthcare professionals, encompassing digestive disease specialists, internists, general practitioners, and certain other medical providers. Established in 2007, the company's corporate offices are situated in Solana Beach, California. ...
Evoke shares jump 16% as William Hill owner agrees £243m takeover by Bally's Intralot
2026-06-05 03:43:13
Evoke PLC (LSE:EVOK), the gambling group that owns William Hill, 888 and Mr Green, has agreed to a £243 million all-share takeover by Bally's Intralot, the Athens-listed lottery and gaming operator, sending its shares 16% higher to 46.45p. The recommended offer values Evoke at 52p per share and includes a partial cash alternative.
Evoke Agrees to $326 Million Takeover Bid From Bally's Intralot
2026-06-05 03:26:00
Evoke shareholders will be entitled to receive 0.537 new Intralot shares for each Evoke share. The deal is expected completed the deal by the first quarter of 2027.
William Hill UK owner Evoke agrees $326 million takeover by Bally's Intralot
2026-06-05 02:11:43
William Hill UK owner Evoke said on Friday it had agreed to be acquired by Bally's Intralot S.A. in a recommended all-share deal valuing the company at about £243 million ($326.23 million).
William Hill owner Evoke in talks with Ball's Intralot about potential takeover
2026-04-20 03:05:13
William Hill owner Evoke PLC (LSE:EVOK) has confirmed it is in talks about being taken over by Greek-US lottery and gambling outfit Bally's Intralot. The bookmaker said a proposed offer valuing the group at 50p per share is being discussed, via an all-share combination, alongside a partial cash alternative.
William Hill UK owner Evoke confirms $304 million takeover bid from Bally's Intralot
2026-04-20 02:27:50
William Hill UK and 888 owner Evoke confirmed on Monday that it is in talks with Greek lottery and gaming firm Bally's Intralot regarding a takeover proposal at 50 pence-per-share, valuing the betting group at 225.3 million pounds ($303.88 million).
Frequently Asked Questions
-
What is the current Evoke Pharma, Inc. (EVOK) stock price?
-
Evoke Pharma, Inc.(NASDAQ:EVOK) stock price is $11 in the last trading session. During the trading session, EVOK stock reached the peak price of $11 while $1.94 was the lowest point it dropped to. The percentage change in EVOK stock occurred in the recent session was 0% while the dollar amount for the price change in EVOK stock was $11.
-
EVOK's industry and sector of operation?
-
The NASDAQ listed EVOK is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of EVOK?
-
Mark A. Kowieski | Chief Financial Officer, Treasurer & Secretary
Matthew J. D'Onofrio | Co-Founder, Chief Executive Officer & Director
Christopher Quesenberry | Chief Commercial Officer - Gimoti (TM)
Marilyn R. Carlson | Chief Medical Officer
| -
How many employees does EVOK have?
-
Number of EVOK employees currently stands at 3. EVOK operates from 420 Stevens Avenue, Solana Beach, CA 92075, US.
-
Link for EVOK official website?
-
Official Website of EVOK is: https://www.evokepharma.com
-
How do I contact EVOK?
-
EVOK could be contacted at phone #858 345 1494 and can also be accessed through its website. EVOK operates from 420 Stevens Avenue, Solana Beach, CA 92075, US.
-
How many shares of EVOK are traded daily?
-
The average number of EVOK shares traded daily for last 3 months was 100.37K.
-
What is the market cap of EVOK currently?
-
The market value of EVOK currently stands at $18.95M with its latest stock price at $11